These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 18494280)

  • 1. [Effect of eprosartan on thrombocytes aggregative capacity in patients with arterial hypertension and metabolic syndrome].
    Simonenko VB; Medvedev IN; Kumova TA
    Klin Med (Mosk); 2008; 86(4):19-21. PubMed ID: 18494280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of eprosartan on psychophysiological functions of drivers with arterial hypertension].
    Tsfasman AZ; At'kova EO; Gutnikova OV
    Kardiologiia; 2006; 46(10):18-20. PubMed ID: 17159852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of irbesartan of the function of hemocoagulative component of hemostasis in patients with arterial hypertension during metabolic syndrome].
    Simonenko VB; Medvedev IN; Tolmachev VV
    Klin Med (Mosk); 2010; 88(6):27-30. PubMed ID: 21395024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin blockade with eprosartan: vascular and functional implications.
    Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
    Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
    Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients.
    Fogari R; Zoppi A; Ferrari I; Mugellini A; Preti P; Lazzari P; Derosa G
    Horm Metab Res; 2009 Dec; 41(12):893-8. PubMed ID: 19708000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [An AT-II blocker in patients with type II diabetes and arterial hypertension].
    Ametov AS; Demidova TIu; Kosykh SA
    Klin Med (Mosk); 2006; 84(2):50-5. PubMed ID: 16613007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teveten (eprosartan) reduces future risk in hypertensive stroke patients.
    Cardiovasc J S Afr; 2004; 15(5):255-6. PubMed ID: 15483740
    [No Abstract]   [Full Text] [Related]  

  • 9. Eprosartan: a review of its use in the management of hypertension.
    Robins GW; Scott LJ
    Drugs; 2005; 65(16):2355-77. PubMed ID: 16266204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction.
    Voors AA; van de Wal RM; Hartog JW; Vijn RG; Hummel YM; Plokker TW; van Veldhuisen DJ; Jaarsma W
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):33-40. PubMed ID: 20229056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
    Shlyakhto E
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S13-8. PubMed ID: 18093409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial).
    Ambrosioni E; Bombelli M; Cerasola G; Cipollone F; Ferri C; Grazioli I; Leprotti C; Mancia G; Melzi G; Mugellini A; Mulè G; Palasciano G; Salvetti A; Trimarco B
    Adv Ther; 2010 Jun; 27(6):365-80. PubMed ID: 20556561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical profile of eprosartan: a different angiotensin II receptor blocker.
    Blankestijn PJ; Rupp H
    Cardiovasc Hematol Agents Med Chem; 2008 Oct; 6(4):253-7. PubMed ID: 18855637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
    Schrader J; Lüders S; Kulschewski A; Hammersen F; Plate K; Berger J; Zidek W; Dominiak P; Diener HC;
    Stroke; 2005 Jun; 36(6):1218-26. PubMed ID: 15879332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
    de la Sierra A; Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
    Ram CV; Rudmann MA
    Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1003-11. PubMed ID: 18035916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure.
    Hollenberg NK
    Curr Hypertens Rep; 2001 Sep; 3 Suppl 1():S25-8. PubMed ID: 11580885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of eprosartan on target organ protection.
    de la Sierra A
    Vasc Health Risk Manag; 2006; 2(1):79-85. PubMed ID: 17319472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study.
    Garg JP; Ellis R; Elliott WJ; Hasabou N; Chua D; Chertow GM; Bakris GL
    Am J Nephrol; 2005; 25(4):393-9. PubMed ID: 16088080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
    Rupp H
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S25-9. PubMed ID: 18093411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.